+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Sanofi (SAN) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 100 Pages
  • June 2024
  • GlobalData
  • Sanofi S.A.
  • ID: 2114215
Sanofi (SAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, multiple sclerosis; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals, and supplements. Sanofi's R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Africa, Asia-Pacific, and the Middle East. Sanofi is headquartered in Paris, Ile-de-France, France.

Sanofi Key Recent Developments

  • Jun 04, 2024: Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in Research
  • May 30, 2024: Sanofi Opens New Advanced Vaccines Facility, Strengthening Its Commitment to Biomanufacturing in Canada
  • May 13, 2024: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty
  • Apr 25, 2024: Sanofi Q1: Robust 7% Sales Growth Driven by Launches, Underpins Full-Year Guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Sanofi - Key Facts
  • Sanofi - Key Employees
  • Sanofi - Key Employee Biographies
  • Sanofi - Major Products and Services
  • Sanofi - History
  • Sanofi - Company Statement
  • Sanofi - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Affiliate
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Sanofi - Business Description
  • Business Segment: Biopharma
  • Overview
  • Performance
  • Business Segment: Consumer Healthcare
  • Overview
  • Performance
  • Geographical Segment: Europe
  • Target Markets
  • Performance
  • Geographical Segment: Rest of the World
  • Target Markets
  • Performance
  • Geographical Segment: United States
  • Performance
  • R&D Overview
  • Sanofi - Corporate Strategy
  • Sanofi - SWOT Analysis
  • SWOT Analysis - Overview
  • Sanofi - Strengths
  • Sanofi - Weaknesses
  • Sanofi - Opportunities
  • Sanofi - Threats
  • Sanofi - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Sanofi, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Sanofi, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jun 04, 2024: Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in Research
  • May 30, 2024: Sanofi Opens New Advanced Vaccines Facility, Strengthening Its Commitment to Biomanufacturing in Canada
  • May 13, 2024: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty
  • Apr 25, 2024: Sanofi Q1: Robust 7% Sales Growth Driven by Launches, Underpins Full-Year Guidance
  • Apr 17, 2024: IGM and Sanofi collaboration will pivot to immunology and inflammation
  • Apr 16, 2024: Sanofi Canada invests $180M CAD to build and update infrastructure to minimize environmental footprint at its Toronto Campus by 50%
  • Mar 14, 2024: Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment for Out-Licensing
  • Feb 22, 2024: Sanofi’s Board of Directors Proposes the Appointment of Clotilde Delbos, Anne-Francoise Nesmes and John Sundy as Independent Directors
  • Feb 01, 2024: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
  • Feb 01, 2024: Francois-Xavier Roger Appointed Chief Financial Officer, Member of Sanofi Executive Committee
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Sanofi, Key Facts
  • Sanofi, Key Employees
  • Sanofi, Key Employee Biographies
  • Sanofi, Major Products and Services
  • Sanofi, History
  • Sanofi, Other Locations
  • Sanofi, Subsidiaries
  • Sanofi, Affiliate
  • Sanofi, Joint Venture
  • Sanofi, Key Competitors
  • Sanofi, Ratios based on current share price
  • Sanofi, Annual Ratios
  • Sanofi, Interim Ratios
  • Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Sanofi, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Sanofi, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Sanofi, Performance Chart (2019 - 2023)
  • Sanofi, Ratio Charts
  • Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Sanofi, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AstraZeneca Plc
  • Qiagen Marseille SA
  • Indivior Plc
  • GSK plc
  • Amgen Inc
  • Merck & Co Inc
  • Johnson & Johnson
  • Boehringer Ingelheim International GmbH
  • Bayer AG
  • Novartis AG
  • Lumos Pharma Inc
  • Heska Corp
  • Receptos Inc
  • Pfizer Inc
  • Novo Nordisk AS
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Co
  • Bristol-Myers Squibb Co
  • Innocoll Holdings Ltd
  • Groupe SOLACTIS SAS
  • Correvio Pharma Corp